Lyra Therapeutics (LYRA) Operating Expenses (2021 - 2025)
Historic Operating Expenses for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $6.3 million.
- Lyra Therapeutics' Operating Expenses fell 5044.71% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year decrease of 6509.6%. This contributed to the annual value of $97.9 million for FY2024, which is 4252.31% up from last year.
- Latest data reveals that Lyra Therapeutics reported Operating Expenses of $6.3 million as of Q3 2025, which was down 5044.71% from $9.0 million recorded in Q2 2025.
- Over the past 5 years, Lyra Therapeutics' Operating Expenses peaked at $49.6 million during Q2 2024, and registered a low of $6.3 million during Q3 2025.
- Moreover, its 5-year median value for Operating Expenses was $13.9 million (2021), whereas its average is $15.4 million.
- In the last 5 years, Lyra Therapeutics' Operating Expenses soared by 19227.05% in 2024 and then plummeted by 8182.64% in 2025.
- Over the past 5 years, Lyra Therapeutics' Operating Expenses (Quarter) stood at $13.9 million in 2021, then grew by 9.04% to $15.2 million in 2022, then rose by 9.61% to $16.6 million in 2023, then tumbled by 30.11% to $11.6 million in 2024, then tumbled by 46.1% to $6.3 million in 2025.
- Its Operating Expenses stands at $6.3 million for Q3 2025, versus $9.0 million for Q2 2025 and $9.0 million for Q1 2025.